News

Sarepta Didn’t Tell Investors About a Patient Death. Wall Street is Furious.
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...
STAT40m
Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
Precision Medicine Online40m
Sarepta Shares Drop on Reports of Patient Death in Gene Therapy Trial
A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.